Shionogi Inc v. Lupin Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Shionogi Inc. (Delaware)
  • Defendant: Lupin Limited (India) and Lupin Pharmaceuticals, Inc. (Florida)
  • Plaintiff's Counsel: FBT Gibbons LLP
• Case Name: Shionogi Inc. v. Lupin Ltd.
• Case Identification: 2:26-cv-03893, D.N.J., 04/13/2026
• Venue Allegations: Venue is asserted based on Defendant Lupin Pharmaceuticals, Inc. having a regular and established place of business in New Jersey and both defendants having previously consented to venue by litigating in the district. For Defendant Lupin Limited, venue is also asserted on the basis of its status as a foreign corporation.
• Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of the drug RADICAVA ORS® constitutes an act of infringement of two patents related to pharmaceutical compositions and methods for oral administration of edaravone.
• Technical Context: The technology concerns oral formulations of edaravone, a treatment for amyotrophic lateral sclerosis (ALS), and specific dosing regimens designed to mitigate the effects of food on the drug's absorption and bioavailability.
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendants' submission of ANDA No. 219415 with a Paragraph IV certification, seeking to market a generic version of RADICAVA ORS® prior to the expiration of the patents-in-suit. The patents are listed in the FDA's Orange Book for RADICAVA ORS®. Plaintiff Shionogi Inc. recently acquired the RADICAVA ORS® business and associated patents from Tanabe Pharma Corporation, which had previously filed related infringement actions against other generic manufacturers. The drug also benefits from FDA Orphan Drug Exclusivity until May 2029.

Case Timeline

Date	Event
2020-11-12	Priority Date for '611 and '769 Patents
2022-05-12	FDA grants approval for RADICAVA ORS® (NDA No. 215446)
2022-09-01	Lupin submits FOIA request for RADICAVA ORS® approval summary
2024-03-28	FDA grants Orphan Drug Exclusivity for RADICAVA ORS®
2025-11-25	U.S. Patent No. 12,478,611 Issues
2026-01-20	U.S. Patent No. 12,527,769 Issues
2026-02-27	Lupin sends Notice Letter regarding ANDA No. 219415
2026-04-01	Shionogi acquires the RADICAVA ORS® business
2026-04-13	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,478,611

• Patent Identification: U.S. Patent No. 12,478,611, "Pharmaceutical composition for oral administration of edaravone and method of administering same," issued November 25, 2025 Compl. ¶38 '611 Patent, cover page

The Invention Explained

• Problem Addressed: The patent background notes that edaravone, a therapeutic agent for oxidative stress diseases like ALS, was available "only in the form of an injectable agent" '611 Patent, col. 1:59-61 A key challenge for developing an oral version is that food consumption can significantly and variably affect the drug's absorption, complicating reliable dosing.
• The Patented Solution: The invention provides a method for administering an oral liquid formulation of edaravone that mitigates this food effect. It achieves this by specifying distinct time intervals between meal consumption and drug administration, tailored to the type of meal (e.g., high-fat, standard, or light), in order to produce pharmacokinetics (PK) comparable to those achieved under fasting conditions '611 Patent, abstract '611 Patent, col. 2:1-9 Clinical data presented in the patent, including Figure 1, demonstrates how different meal types and timings influence the drug's maximum concentration (Cmax) '611 Patent, FIG. 1
• Technical Importance: This dosing method enables consistent and predictable absorption of an oral form of edaravone, offering a significant quality-of-life improvement for ALS patients by replacing intravenous injections with a more convenient oral regimen Compl. ¶11

Key Claims at a Glance

• The complaint asserts infringement of at least Independent Claim 1 Compl. ¶48
• Essential elements of Independent Claim 1 include:
  • A method for treating amyotrophic lateral sclerosis.
  • Orally or intragastrically administering a liquid pharmaceutical composition comprising edaravone.
  • Administration occurs after a "first time interval" following consumption of a meal.
  • This time interval is chosen to achieve "the same pharmacokinetics" (including Cmax and AUC) as administration under fasting conditions.
  • The dose of edaravone is between 90 mg and 120 mg.
  • Specific time intervals are defined: ≥8 hours for a high-fat meal, ≥4 hours for a standard meal, and ≥2 hours for a light meal.

U.S. Patent No. 12,527,769

• Patent Identification: U.S. Patent No. 12,527,769, "Pharmaceutical composition for oral administration of edaravone and method of administering same," issued January 20, 2026 Compl. ¶39 '769 Patent, cover page

The Invention Explained

• Problem Addressed: Similar to the '611 Patent, the invention addresses the need for a reliable oral dosing regimen for edaravone that accounts for the impact of food on the drug's pharmacokinetics '769 Patent, col. 1:21-61
• The Patented Solution: The '769 Patent claims a method of administering a liquid edaravone suspension using specific pre-dosing time intervals after meals. Unlike the '611 Patent, which requires achieving "the same pharmacokinetics" as fasting, this patent's lead claim defines the successful outcome differently: the timing must result in a decrease in Cmax of less than 20% and/or a decrease in AUC of less than 10% compared to fasting conditions '769 Patent, claim 1 The specification details the composition of the suspension, including edaravone particles, a dispersing agent, and water '769 Patent, col. 5:7-9
• Technical Importance: By defining a specific formulation type (suspension) and a quantitative standard for mitigating the food effect, the invention provides a clear, measurable method for ensuring consistent therapeutic exposure with oral edaravone Compl. ¶11

Key Claims at a Glance

• The complaint asserts infringement of at least Independent Claim 1 Compl. ¶59
• Essential elements of Independent Claim 1 include:
  • A method for treating amyotrophic lateral sclerosis.
  • Orally or intragastrically administering a liquid pharmaceutical composition that is a "suspension comprising the edaravone."
  • Administration occurs after a "first time interval" following a meal (high-fat, low-fat, or caloric supplement).
  • The time interval is chosen such that the decrease in Cmax is less than 20% and/or the decrease in AUC is less than 10%, relative to administration in a fasting state.

III. The Accused Instrumentality

Product Identification

• Defendants' proposed edaravone oral suspension, which is the subject of ANDA No. 219415 Compl. ¶41

Functionality and Market Context

• The accused product is a proposed generic copy of Plaintiff's RADICAVA ORS®, intended for the treatment of ALS Compl. ¶40 Compl. ¶43 It is formulated as an oral suspension with a dose concentration of 105 mg/5 mL Compl. ¶41 The act of infringement alleged in the complaint is the submission of the ANDA itself, which seeks FDA approval to market this generic version before the expiration of the patents-in-suit Compl. ¶2 Compl. ¶50 The commercial context is that of a generic drug seeking to compete with an established branded product that offers a clinically superior oral administration route for a serious disease Compl. ¶12 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges that the submission of ANDA No. 219415 constitutes infringement of the patents-in-suit under 35 U.S.C. § 271(e)(2) and that future commercialization will constitute direct and induced infringement (Compl. ¶49; Compl. ¶50; Compl. ¶51; Compl. ¶52). The infringement theory for the asserted method claims relies on the allegation that Defendants' proposed product label will necessarily instruct physicians and patients to administer the drug in a manner that performs the steps of the patented methods Compl. ¶49 Compl. ¶60 The complaint does not contain a detailed element-by-element infringement analysis. The following chart summarizes the infringement theory as inferred from the complaint's allegations and the nature of ANDA litigation.

'611 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating amyotrophic lateral sclerosis, comprising: orally or intragastrically administering, to a subject in need thereof, a liquid pharmaceutical composition comprising edaravone...	Defendants' ANDA product is a liquid edaravone suspension (105 mg/5 mL) seeking approval for the treatment of ALS, the same indication as the reference drug RADICAVA ORS®.	¶41; ¶43	col. 1:21-28
with a first time interval from a consumption of a meal... to an administration... such that the first time interval achieves the same pharmacokinetics as administration... under a fasting condition...	The complaint alleges that the proposed product label will instruct administration according to the patented dosing intervals, which are designed to achieve pharmacokinetics equivalent to fasting, thereby inducing infringement.	¶49	col. 6:1-17
wherein... a dose of edaravone per administration is in a range of 90 to 120 mg...	The accused product is administered at a dose concentration of 105 mg/5 mL, which falls within the claimed dosage range.	¶41	col. 12:65

'769 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating amyotrophic lateral sclerosis, comprising: orally or intragastrically administering, to a subject in need thereof, a liquid pharmaceutical composition comprising edaravone...	Defendants' ANDA product is a liquid edaravone suspension seeking approval for the treatment of ALS, matching the claimed method and indication.	¶41; ¶43	col. 33:20-25
wherein the liquid pharmaceutical composition is a suspension comprising the edaravone...	The ANDA product is identified in the complaint as a "proposed edaravone suspension."	¶41	col. 34:1-12
and the first time interval... is 8 hours before... a high-fat meal... OR... 4 hours before... a low-fat meal... OR... 2 hours before... a caloric supplement... such that a decrease in Cmax is less than 20%... and/or... a decrease in AUC is less than 10%...	The complaint's theory of induced infringement alleges that the product's label will instruct administration according to the patented time intervals, which are asserted to result in the claimed pharmacokinetic outcomes.	¶60	col. 34:13-30

• Identified Points of Contention:
  • Scope Questions: An issue for the court may be whether the instructions on Defendants' proposed label, which must be substantially similar to the label for RADICAVA ORS®, direct or encourage all the steps of the asserted method claims, including the specific meal-timing and resulting pharmacokinetic outcomes.
  • Technical Questions: A central factual dispute may be whether administration of the accused product according to its label instructions actually results in the claimed pharmacokinetic performance. For the '611 Patent, this involves determining if it achieves "the same pharmacokinetics" as fasting. For the '769 Patent, this requires evidence that the resulting Cmax and AUC decreases are within the claimed percentage limits.

V. Key Claim Terms for Construction

• The Term: "the same pharmacokinetics" '611 Patent, claim 1

• Context and Importance: This term defines the required outcome of the method in Claim 1 of the '611 Patent. The infringement analysis will depend heavily on whether the administration of Defendants' product achieves this standard. Practitioners may focus on this term because its definition-whether it requires near-identity or allows for statistical bioequivalence-is central to proving infringement.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification provides a definition consistent with regulatory standards for bioequivalence, stating that "statistically the same level to common criteria for bioequivalence (e.g., a least squares mean ratio and its 90% confidence interval are in the range of 0.8 to 1.25)" constitutes "the same pharmacokinetics" '611 Patent, col. 6:11-17
  • Evidence for a Narrower Interpretation: The patent also presents clinical data in tables where the mean Cmax and AUC values for certain post-meal administrations are numerically very close to the fasted state '611 Patent, Table 2 A party could argue these specific results, rather than the general bioequivalence standard, define the term's scope more narrowly.

• The Term: "suspension" '769 Patent, claim 1

• Context and Importance: Claim 1 of the '769 Patent is limited to a "suspension." Infringement hinges on whether Defendants' product meets the technical definition of this term as used in the patent.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The patent describes a suspension as comprising "edaravone particles, a dispersing agent and water" '769 Patent, col. 5:7-9 This general description could be argued to encompass a wide range of formulations.
  • Evidence for a Narrower Interpretation: The specification provides a detailed exemplary composition, including specific excipients like polyvinyl alcohol, xanthan gum, and sorbitol, and discusses preferred particle sizes '769 Patent, col. 9:1-20 '769 Patent, col. 13:25-37 A party could argue that the term "suspension" should be construed in light of these specific, preferred embodiments.

VI. Other Allegations

• Indirect Infringement: The complaint alleges active inducement of infringement under 35 U.S.C. § 271(b). The factual basis for this claim is that Defendants' proposed product labeling will instruct, encourage, and promote the administration of the drug by physicians and patients in a manner that directly infringes the asserted method claims Compl. ¶49 Compl. ¶60
• Willful Infringement: Willfulness is alleged based on Defendants' knowledge of the patents-in-suit prior to amending their ANDA to include a Paragraph IV certification Compl. ¶53 Compl. ¶64 The complaint asserts that Defendants' submission constituted infringement despite an "objectively high likelihood" of such, and that this risk "was either known to Lupin or so obvious that it should have been known" Compl. ¶53 Compl. ¶64

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of claim scope and infringement: can the pharmacokinetic outcomes required by the claims-"the same pharmacokinetics" in the '611 Patent and the specific percentage-based criteria in the '769 Patent-be proven to result from the administration of Defendants' generic product as directed by its proposed label?
• A key evidentiary question will be one of induced infringement: does the proposed label for the generic product provide sufficiently clear instruction and encouragement to establish that Defendants possess the specific intent to induce doctors and patients to perform the patented methods?
• A central point of contention will likely revolve around the interpretation of clinical data: the parties will likely dispute the meaning of the pharmacokinetic data presented in the patents and its relationship to the language of the claims, forming the basis for arguments on both infringement and validity.